Replimune Group
REPL
112 hedge funds and large institutions have $1.32B invested in Replimune Group in 2020 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 45 increasing their positions, 16 reducing their positions, and 10 closing their positions.
340% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 10
181% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 16
115% more capital invested
Capital invested by funds: $612M → $1.32B (+$704M)
44% more funds holding
Funds holding: 78 → 112 (+34)
9.01% more ownership
Funds ownership: 66.02% → 75.03% (+9%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$91.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$71.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$52.6M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$30.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$29.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$48.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$38.9M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$11.3M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$8.98M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$8.59M |
REPL Hedge Fund Activity: Q4 2020 in Review
112 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q4 2020, worth a combined $1.32B — up 115% from $612M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new REPL positions and 10 closed out — a net gain of 34 holders — while 45 added to existing stakes and 16 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $91.7M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $48.9M sold.
- 112 institutional investors held Replimune Group (REPL) as of Q4 2020, up from 78 in Q3 2020.
- Funds reported $1.32B of Replimune Group stock for Q4 2020, up 115% quarter-over-quarter.
- 44 funds opened new Replimune Group positions in Q4 2020 and 10 closed out, a net change of +34 holders.
- The largest Replimune Group buyer in Q4 2020 was T. Rowe Price Associates, an estimated $91.7M added.
- The largest Replimune Group seller in Q4 2020 was Bain Capital Life Sciences Investors, an estimated $48.9M sold.
Based on aggregated 13F filings for Q4 2020.